Mycotopia Therapies (formerly 20/20 Global Inc.), a subsidiary of digital therapeutics company EHAVE Inc., is a psychedelic company engaged in psychedelic research and development of psychedelic experiential therapies. The company is researching the use of psychedelics to treat post-traumatic stress disorder (PTSD), severe anxiety, depression, and serotonin syndrome.
As part of a joint venture with psychedelic research and development company Natural MedTech, the company established PsyBioMed, a biosynthetic compound subsidiary in February 2021, to manufacture, license, and commercialize genetically optimized yeast to produce psychedelics. It also operates multiple retreats around the world offering psychedelic-assisted psychotherapies and experiences facilitated by professional medical practitioners.
Mycotopia entered into a supply agreement with psychedelic company HAVN Life Sciences, in August 2021, to receive naturally-derived medicinal psilocybin. It plans to distribute psilocybe compounds to universities, researchers, and companies.
Based in Miami, the company began trading in the Over-The-Counter (OTC) markets in May 2021 under its new name and new symbol “TPIA.”
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.